Cargando…
A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix
Nonalcoholic fatty liver disease, a type of metabolic syndrome, continues to rise globally. Currently, there is no approved drug for its treatment. Improving lifestyle and exercise can alleviate symptoms, but patients' compliance is poor. More and more studies have shown the potential of Polygo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193283/ https://www.ncbi.nlm.nih.gov/pubmed/32382557 http://dx.doi.org/10.1155/2020/5462063 |
_version_ | 1783528164766515200 |
---|---|
author | Zhou, Mengting Hu, Naihua Liu, Meichen Deng, Ying He, Linfeng Guo, Chaocheng Zhao, Xingtao Li, Yunxia |
author_facet | Zhou, Mengting Hu, Naihua Liu, Meichen Deng, Ying He, Linfeng Guo, Chaocheng Zhao, Xingtao Li, Yunxia |
author_sort | Zhou, Mengting |
collection | PubMed |
description | Nonalcoholic fatty liver disease, a type of metabolic syndrome, continues to rise globally. Currently, there is no approved drug for its treatment. Improving lifestyle and exercise can alleviate symptoms, but patients' compliance is poor. More and more studies have shown the potential of Polygoni Multiflori Radix (PMR) in the treatment of NAFLD and metabolic syndrome. Therefore, this paper reviews the pharmacological effects of PMR and its main chemical components (tetrahydroxystilbene glucoside, emodin, and resveratrol) on NAFLD. PMR can inhibit the production of fatty acids and promote the decomposition of triglycerides, reduce inflammation, and inhibit the occurrence of liver fibrosis. At the same time, it maintains an oxidation equilibrium status in the body, to achieve the therapeutic purpose of NAFLD and metabolic syndrome. Although more standardized studies and clinical trials are needed to confirm its efficacy, PMR may be a potential drug for the treatment of NAFLD and its complications. However, the occurrence of adverse reactions of PMR has affected its extensive clinical application. Therefore, it is necessary to further study its toxicity mechanism, enhance efficacy and control toxicity, and even reduce toxicity, which will contribute to the safe clinical use of PMR. |
format | Online Article Text |
id | pubmed-7193283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-71932832020-05-07 A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix Zhou, Mengting Hu, Naihua Liu, Meichen Deng, Ying He, Linfeng Guo, Chaocheng Zhao, Xingtao Li, Yunxia Biomed Res Int Review Article Nonalcoholic fatty liver disease, a type of metabolic syndrome, continues to rise globally. Currently, there is no approved drug for its treatment. Improving lifestyle and exercise can alleviate symptoms, but patients' compliance is poor. More and more studies have shown the potential of Polygoni Multiflori Radix (PMR) in the treatment of NAFLD and metabolic syndrome. Therefore, this paper reviews the pharmacological effects of PMR and its main chemical components (tetrahydroxystilbene glucoside, emodin, and resveratrol) on NAFLD. PMR can inhibit the production of fatty acids and promote the decomposition of triglycerides, reduce inflammation, and inhibit the occurrence of liver fibrosis. At the same time, it maintains an oxidation equilibrium status in the body, to achieve the therapeutic purpose of NAFLD and metabolic syndrome. Although more standardized studies and clinical trials are needed to confirm its efficacy, PMR may be a potential drug for the treatment of NAFLD and its complications. However, the occurrence of adverse reactions of PMR has affected its extensive clinical application. Therefore, it is necessary to further study its toxicity mechanism, enhance efficacy and control toxicity, and even reduce toxicity, which will contribute to the safe clinical use of PMR. Hindawi 2020-04-20 /pmc/articles/PMC7193283/ /pubmed/32382557 http://dx.doi.org/10.1155/2020/5462063 Text en Copyright © 2020 Mengting Zhou et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Zhou, Mengting Hu, Naihua Liu, Meichen Deng, Ying He, Linfeng Guo, Chaocheng Zhao, Xingtao Li, Yunxia A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix |
title | A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix |
title_full | A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix |
title_fullStr | A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix |
title_full_unstemmed | A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix |
title_short | A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix |
title_sort | candidate drug for nonalcoholic fatty liver disease: a review of pharmacological activities of polygoni multiflori radix |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193283/ https://www.ncbi.nlm.nih.gov/pubmed/32382557 http://dx.doi.org/10.1155/2020/5462063 |
work_keys_str_mv | AT zhoumengting acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT hunaihua acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT liumeichen acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT dengying acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT helinfeng acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT guochaocheng acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT zhaoxingtao acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT liyunxia acandidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT zhoumengting candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT hunaihua candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT liumeichen candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT dengying candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT helinfeng candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT guochaocheng candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT zhaoxingtao candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix AT liyunxia candidatedrugfornonalcoholicfattyliverdiseaseareviewofpharmacologicalactivitiesofpolygonimultifloriradix |